Stocktoria
Indivior Pharmaceuticals, Inc. INDV
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2023-06-12
Chart by TradingView
4/9
Piotroski F — financial health
-0.7
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Revenue | $1.2B | $1.2B | $1.1B |
| Gross profit | $994.0M | $957.0M | $919.0M |
| Operating income | $262.0M | $38.0M | -$152.0M |
| Net income | $210.0M | $7.0M | -$126.0M |
| Operating cash flow | -$27.0M | $36.0M | -$300.0M |
| Free cash flow | -$93.0M | $7.0M | -$308.0M |
| Total assets | $1.2B | $1.3B | $1.8B |
| Total liabilities | $1.3B | $1.7B | $1.9B |
| Shareholders' equity | -$98.0M | -$337.0M | -$184.0M |
| Ratios | |||
| Gross margin | 80.2% | 80.6% | 84.1% |
| Operating margin | 21.1% | 3.2% | -13.9% |
| Net margin | 16.9% | 0.6% | -11.5% |
| FCF margin | -7.5% | 0.6% | -28.2% |
| Return on assets | 17.5% | 0.5% | -7.2% |
| Return on equity | -214.3% | -2.1% | 68.5% |
| Debt / equity | -2.96× | -0.93× | -1.29× |
| Current ratio | 0.71 | 0.90 | 0.98 |
| Revenue growth | 4.3% | 8.7% | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 94,943 | $2.9M |
| Bridgewater Associates, LP | 37,141 | $1.1M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.7 (distress)
- Working capital / assets -0.218
- Retained earnings / assets -0.202
- EBIT / assets 0.218
- Equity / liabilities -0.075
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001625297 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.